Drug intelligence / Profile preview

Melats P

Development stage: Phase 1
Lead developer: Jinnah Postgraduate Medical Centre
Modality: Small Molecules
Administration: Oral

Overview

Melats P is a polyherbal formulation developed by the Jinnah Postgraduate Medical Centre for the management of Polycystic Ovary Syndrome (PCOS). As a combination of herbal medications, it is designed to address the complex metabolic and reproductive symptoms associated with PCOS, including hyperandrogenism, chronic anovulation, and insulin resistance. Clinical research, including Phase 1 trials, has evaluated Melats P both as a monotherapy and as an adjunct to Metformin XR to improve fertility outcomes and metabolic parameters in women of reproductive age. The formulation aims to provide a therapeutic alternative or enhancement to standard treatments for PCOS-related infertility and metabolic disturbances.

Brand names: Melats P
Other names: Herbal Formulation

Beyond the preview

Go deeper on Melats P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melats P.

Explore the full profile